Advertisement

Search Results

Advertisement



Your search for all items matches 1598 pages

Showing 251 - 300


breast cancer

Breast Pathologic Complete Response and Pathologic Node Positivity After Neoadjuvant Therapy

In a National Cancer Database analysis reported in JAMA Surgery, Barron et al found low pathologic nodal positivity rates among patients with clinically node-negative (cN0), HER2-positive disease or triple-negative breast cancer with breast pathologic complete response (pCR) after neoadjuvant...

breast cancer
immunotherapy

Sequential vs Concurrent Neoadjuvant Therapy in HER2-Positive Breast Cancer

As reported in JAMA Oncology by Buzdar et al, the phase III ACOSOG Z1041 (Alliance) trial showed no difference in disease-free or overall survival with sequential vs concurrent neoadjuvant anthracycline and trastuzumab in patients with operable HER2-positive breast cancer. An earlier report from...

breast cancer

Danish Study on Effect of Screening on Breast Cancer Mortality

In a Danish study reported in the Journal of Clinical Oncology, Beau et al used different models to assess the effects of screening on breast cancer mortality, finding a 20% reduction among patients diagnosed during the recommended screening age range. As noted by the investigators, the study was...

breast cancer

10-Year Follow-up of Axillary Dissection vs No Dissection in Breast Cancer With Sentinel Node Micrometastases

In the 10-year follow-up of the phase III International Breast Cancer Study Group (IBCSG) 23-01 trial reported in The Lancet Oncology, Galimberti et al found no significant difference in disease-free survival with axillary dissection vs no axillary dissection in patients with breast cancer and...

breast cancer

Somatic Mutations in ER-Positive Breast Cancer and Prognosis

Recent research and genomic studies have revealed a number of genes that accumulate somatic mutations and alterations in estrogen receptor (ER)–positive breast cancer. However, while a few alterations are quite common and relatively well-understood, many genes are mutated in less than 5% of...

breast cancer

Proteomics May Be Used to Predict Treatment Outcomes in Triple-Negative Breast Cancer

In triple-negative breast cancer, researchers have so far been unable to identify markers that can classify patients by prognosis or probability of responding to different treatments. In a study published by Zagorac et al in Nature Communications, researchers from the Spanish National Cancer...

breast cancer

Rates of Inherited Breast Cancer in Nigerian Women

In a study reported in the Journal of Clinical Oncology, Zheng et al found a high frequency of inherited breast cancer among Nigerian women, with presence of deleterious mutations posing very high risk of disease. As noted by the investigators, “…Among Nigerian women, breast cancer is ...

breast cancer
immunotherapy

Adding First-Line Pertuzumab to Trastuzumab Plus Aromatase Inhibitor in Advanced Breast Cancer

In the phase II PERTAIN trial reported in the Journal of Clinical Oncology, Rimawi et al found that adding pertuzumab to trastuzumab plus an aromatase inhibitor improved progression-free survival in patients with advanced HER2-positive, hormone receptor–positive breast cancer. Study Details ...

breast cancer

EMBRACA Trial Compares Talazoparib vs Standard Therapy in Advanced Breast Cancer With a Germline BRCA Mutation

As reported in The New England Journal of Medicine by Litton et al, the phase III EMBRACA trial has shown significantly improved progression-free survival with the poly (ADP-ribose) polymerase inhibitor talazoparib vs physician choice of standard single-agent therapy in patients with advanced...

breast cancer

Dutch Quality-of-Life Study With One- vs Two-Stage Breast Reconstruction in Skin-Sparing Mastectomy

In a Dutch study reported in The Lancet Oncology, Negenborn et al found no differences in quality of life (QOL) between women receiving one-stage implant-based breast reconstruction (IBBR) with an acellular dermal matrix (ADM) vs standard two-stage IBBR. A previously reported safety analysis from...

breast cancer
gynecologic cancers
issues in oncology

BRCA Testing in Medically Underserved Women in Southeastern United States

Medically underserved women in the Southeast region of the United States diagnosed with breast cancer or ovarian cancer may have not received genetic testing that could have helped them and their relatives make important decisions about their health, according to new research from Vanderbilt-Ingram ...

breast cancer

FDA Grants Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis

iCAD has announced U.S. Food and Drug Administration (FDA) clearance of its artificial intelligence software program, PowerLook Density Assessment Version 3.4, which provides an automated method of determining breast density. The software is compatible with iCAD’s digital breast...

breast cancer
issues in oncology

Cardiac Monitoring in Patients With Breast Cancer

Although heart failure is an uncommon complication of breast cancer treatment, the risk may be higher in patients treated with certain types of chemotherapy and lower in younger patients, according to a study published by Henry et al in JACC: Cardiovascular Imaging. Researchers studied 16,456...

breast cancer

ESR1 Fusions and Metastasis in Estrogen Receptor–Positive Breast Cancer

Estrogen receptor–positive breast cancer is the most common type of breast cancer, but resistance to therapy is common, and eventual development of metastatic disease is a leading cause of death. In research published by Lei et al in Cell Reports, researchers from Baylor College of...

breast cancer

Circulating Tumor Cells and Late Recurrence in Hormone Receptor–Positive Breast Cancer

In a study reported in JAMA Oncology, Sparano et al found that a single circulating tumor cell (CTC) assessment was predictive of late recurrence in patients with hormone receptor–positive, HER2-negative breast cancer. The study involved patients from a phase III trial of doxorubicin and...

breast cancer

Utilization of Hypofractionated Radiation Therapy in Breast Cancer

Researchers at the Feinstein Institute for Medical Research and Northwell Health’s Department of Radiation Medicine have identified methods to increase use of the radiation therapy hypofractionation in patients with breast cancer. These findings, published by Gilbo et al...

breast cancer

Study Identifies Specific Genes Associated With Increased Risk for Triple-Negative Breast Cancer

Studies show that triple-negative breast cancer is associated with advanced-stage disease and higher-grade tumors at the time of diagnosis, and carries an increased risk of recurrence and poorer 5-year survival rates relative to other breast cancers. This type of breast cancer accounts for...

breast cancer

TGFβ Polymorphism and Radiation-Induced Fibrosis in Breast Cancer

In an analysis reported in JAMA Oncology, Grossberg et al found that a single nucleotide polymorphism (C−509T) in the transforming growth factor β1 (TGFβ1) gene was associated with higher risk of radiation-induced fibrosis in women with early breast cancer. Study Details The...

breast cancer
immunotherapy

Adjuvant Bevacizumab in High-Risk HER2-Negative Breast Cancer

In an article in the Journal of Clinical Oncology, Miller et al reported final results of the Eastern Cooperative Oncology Group phase III E5103 trial, initiated in 2007, which showed no benefit of adding bevacizumab (Avastin) to adjuvant therapy in patients with HER2-negative, node-positive or...

breast cancer
gastroesophageal cancer
gastrointestinal cancer
immunotherapy

European Commission Approves Trastuzumab Biosimilar

The European Commission (EC) has approved Trazimera, a biosimilar to trastuzumab (Herceptin), for the treatment of human epidermal growth factor (HER2)–overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. This approval...

breast cancer

Psychosocial Effects of Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer

In a prospective study reported in the Journal of Clinical Oncology, Parker et al found that among women with nonhereditary breast cancer electing contralateral prophylactic mastectomy (CPM), fear and worry over breast cancer may be dominant at the time of surgical decisions without sufficient...

breast cancer
colorectal cancer
prostate cancer

Following a Healthy Diet and Avoiding Alcohol May Reduce Overall Cancer Risk

The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) has estimated that in developed countries, about 35% of breast cancers and 45% of colorectal cancers could be prevented with a better adherence to nutritional recommendations. A large prospective study evaluating...

breast cancer

FDA Approves Magnetic Device System for Guiding Sentinel Lymph Node Biopsies in Patients With Breast Cancer

The U.S. Food and Drug Administration (FDA) recently approved a magnetic device system for guiding lymph node biopsies in patients with breast cancer undergoing mastectomy. The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to ...

breast cancer

Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer

In a study reported in JAMA Oncology, Morrow and colleagues found that surgeon acceptance of more limited surgery in early breast cancer was more likely among high-volume surgeons and those preferring a surgical margin of “no ink on tumor.” As noted by the authors, the American College ...

breast cancer

New Study Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40

A new study from the Stanford Cancer Institute found that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive...

breast cancer
symptom management

C-Reactive Protein and Radiotherapy Skin Toxicity in Patients With Breast Cancer

In a study reported in the Journal of Clinical Oncology, Hu et al found that higher postradiotherapy levels of the inflammatory marker high-sensitivity C-reactive protein (hsCRP) were associated with an increased risk of early grade 4+ skin toxicity in patients with breast cancer. Study Details...

breast cancer

FDA Accepts BLA, Grants Priority Review for Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) recently accepted a biologics license application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who previously received at least two prior therapies for...

breast cancer

FDA Expands Ribociclib Indication in Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Today, the U.S. Food and Drug Administration (FDA) expanded the indication for ribociclib (Kisqali) in combination with an aromatase inhibitor for premenopausal or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer as initial...

breast cancer

Somatic Driver Alterations and Distant Recurrence in Postmenopausal Early Breast Cancer Patients Receiving Endocrine Therapy

In an analysis from the BIG 1-98 trial reported in JAMA Oncology, Luen et al found that 11q13and 8p11 amplifications were associated with an increased risk of distant recurrence among patients with postmenopausal hormone receptor–positive, HER2-negative breast cancer receiving adjuvant...

breast cancer

ASCO Clinical Practice Guideline Update: Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Sharon H. Giordano, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, ASCO has released a clinical practice guideline update on systemic therapy for patients with advanced HER2-positive breast cancer. The guideline update...

breast cancer

Body Mass Index, Age, and Premenopausal Breast Cancer Risk

In a multicohort study reported by researchers from the Premenopausal Breast Cancer Collaborative Group in JAMA Oncology, Schoemaker et al found that increasing adiposity was associated with a significantly reduced risk of premenopausal breast cancer across the entire spectrum of body mass index...

breast cancer
skin cancer

Flight Attendants May Be at Increased Risk of Breast, Skin Cancers

Flight attendants showed an elevated incidence of several types of cancer compared with the general population, according to findings published by McNeely et al in Environmental Health. “Our findings of higher rates of several cancers among flight attendants is striking given the low rates...

breast cancer

ASCO Clinical Practice Guideline Update: Disease Management for Patients With Advanced HER2-Positive Breast Cancer and Brain Metastases

As reported in the Journal of Clinical Oncology by Naren Ramakrishna, MD, of the University of Florida Health Cancer Center at Orlando Health, and colleagues, ASCO has released a clinical practice guideline update on disease management for patients with advanced HER2-positive breast cancer and...

breast cancer
immunotherapy

IMpassion130: Atezolizumab Plus Nab-Paclitaxel in Metastatic or Locally Advanced Triple-Negative Breast Cancer

The phase III IMpassion130 study has met its co-primary endpoint of progression-free survival (PFS). Results demonstrated that the combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) as first-line treatment significantly reduced the risk of disease worsening or death in patients...

breast cancer

Addition of Panitumumab to Neoadjuvant Chemotherapy in Primary HER2-Negative Inflammatory Breast Cancer

In a single-center phase II study reported in JAMA Oncology, Matsuda et al found that adding the EGFR inhibitor panitumumab (Vectibix) to neoadjuvant chemotherapy produced high pathologic complete response (pCR) rates in patients with primary triple-negative inflammatory breast cancer. Study...

breast cancer
immunotherapy

Trastuzumab Biosimilar vs Reference Trastuzumab in HER2-Positive Early Breast Cancer

In the phase III LILAC equivalence trial reported in The Lancet Oncology, von Minckwitz et al found similar efficacy and safety with the trastuzumab biosimilar ABP 980 vs reference trastuzumab (Herceptin) in HER2-positive early breast cancer. On local review, the risk difference and risk ratio (RR) ...

breast cancer

Addition of Ribociclib to Fulvestrant Improves Progression-Free Survival in HR-Positive, HER2-Negative Advanced Breast Cancer

As reported by Slamon and colleagues in the Journal of Clinical Oncology, the phase III MONALEESA-3 trial has shown significant improvement in progression-free survival with the addition of the CDK4/6 inhibitor ribociclib (Kisqali) to fulvestrant (Faslodex) in hormone receptor (HR)-positive,...

breast cancer

FDA Accepts Supplementary PMA for Review of BRACAnalysis CDx as a Companion Diagnostic to Talazoparib in Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) recently accepted a supplementary premarket approval (PMA) application for BRACAnalysis CDx to be used as a companion diagnostic with the poly ADP ribose polymerase (PARP) inhibitor talazoparib. The new drug application (NDA) for...

breast cancer

Long-Term Results of Adjuvant Endocrine Therapy in Premenopausal Breast Cancer

In an analysis of long-term outcomes in the SOFT and TEXT trials reported at the 2018 ASCO Annual Meeting and in The New England Journal of Medicine, Francis et al found that the addition of ovarian suppression to adjuvant tamoxifen significantly improved 8-year rates of disease-free and overall...

breast cancer

ASCO/CAP Clinical Practice Guideline Focused Update on HER2 Testing in Breast Cancer

As reported in the Journal of Clinical Oncology by Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and colleagues, ASCO and the College of American Pathologists (CAP) have issued a clinical practice guideline focused update on HER2 testing in breast cancer....

breast cancer
solid tumors

FDA Clears Expanded Indication of Scalp-Cooling System

Paxman’s advanced scalp-cooling system has now been cleared by the US Food and Drug Administration (FDA) for use during treatment of patients with solid tumors. The system is now indicated to reduce the likelihood of chemotherapy-induced alopecia in cancer patients with solid tumors such as...

breast cancer
survivorship

Low-Fat Dietary Intervention and Overall Survival After Breast Cancer Diagnosis

In an analysis from the Women’s Health Initiative (WHI) trial reported in JAMA Oncology, Chlebowski et al found that overall survival after the diagnosis of incident breast cancer was improved in women in the reduced-fat dietary intervention group vs control group, reflecting reduced...

breast cancer

FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) recently accepted for filing and granted Priority Review designation a new drug application for talazoparib. The submission is based on results from the EMBRACA trial, which evaluated talazoparib vs chemotherapy in patients with germline BRCA-mutated,...

breast cancer
issues in oncology
survivorship

Study Finds Breast Cancer Survivors Are Not Getting Recommended Number of Mammograms Postsurgery

Breast cancer survivors are not getting the recommended level of screening postsurgery, according to a study by Ruddy et al in JNCCN–Journal of the National Comprehensive Cancer Network. The study was led by Kathryn Ruddy, MD, MPH, Director of Cancer Survivorship for the Department of...

breast cancer
lung cancer

Characteristics and Screening of Brain Metastases in Breast Cancer and NSCLC

In a research letter published in JAMA Oncology, Cagney et al found that brain metastases were more advanced and more likely to be symptomatic in patients with breast cancer compared to patients with non–small cell lung cancer (NSCLC). Current guidelines recommend magnetic resonance imaging...

breast cancer

ASCO Clinical Practice Guideline Focused Update: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer

As reported by Neelima Denduluri, MD, of US Oncology Network, Virginia Cancer Specialists, and colleagues in the Journal of Clinical Oncology, ASCO has issued a focused update on the clinical practice guideline on optimal chemotherapy and targeted therapy in early breast cancer. To develop the...

breast cancer

Andrew D. Seidman, MD, and Meredith M. Regan, ScD, on Breast Cancer: Results From the TEXT and SOFT Trials

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discuss study findings on absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, ...

breast cancer

Andrew D. Seidman, MD, and Susan F. Dent, MD, on Breast Cancer: Analysis of the SANDPIPER Trial

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Susan F. Dent, MD, of The Ottawa Hospital Cancer Centre, analyze the phase III study findings on taselisib plus fulvestrant vs fulvestrant in patients with estrogen receptor–positive, PIK3CA-mutant, locally advanced or metastatic ...

breast cancer

Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Metastatic Breast Cancer: Findings on an Antibody-Drug Conjugate

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discuss the efficacy of sacituzumab govitecan for treatment-refractory hormone receptor–positive/HER2-negative metastatic breast cancer (Abstract 1004).

breast cancer

Michael Gnant, MD, on Breast Cancer: Results From the ABCSG-18 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses study findings on adjuvant denosumab in early breast cancer––a disease-free survival analysis of postmenopausal patients.

Advertisement

Advertisement



Advertisement